Itau Unibanco Holding S.A. Seagen Inc. Transaction History

Itau Unibanco Holding S.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$191.51 - $216.16 $383 - $432	-2 Reduced 0.39%	511 $108,000
Q2 2023 Aug 14, 2023	SELL	$187.64 - $206.25 $375 - $412	-2 Reduced 0.39%	513 $98,000
Q1 2023 May 12, 2023	SELL	$127.59 - $203.08 $255 - $406	-2 Reduced 0.39%	515 $104,000
Q4 2022 Feb 09, 2023	BUY	$117.37 - $139.17 $20,539 - $24,354	175 Added 51.17%	517 $66,000
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $23,131 - $30,798	-171 Reduced 33.33%	342 $47,000
Q2 2022 Aug 15, 2022	SELL	$108.81 - $179.33 $544 - $896	-5 Reduced 0.97%	513 $91,000
Q1 2022 May 16, 2022	BUY	$119.61 - $157.85 $598 - $789	5 Added 0.97%	518 $75,000
Q4 2021 Feb 14, 2022	BUY	$142.57 - $190.86 $33,218 - $44,470	233 Added 83.21%	513 $81,000
Q3 2021 Nov 12, 2021	BUY	$142.45 - $169.82 $14,244 - $16,982	100 Added 55.56%	280 $48,000
Q2 2021 Aug 17, 2021	BUY	$135.08 - $161.1 $24,314 - $28,998	180 New	180 $28,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Itau Unibanco Holding S.A., based on Form 13F filings with the SEC.

Stay updated on Itau Unibanco Holding S.A. with notifications on news.